Syringe driver in Palliative Care

Similar documents
Renal Palliative Care Last Days of Life

SYRINGE DRIVER MEDICATIONS

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Syringe Drivers. Back to top

Care in the Last Days of Life

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Clatterbridge Centre for Oncology

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Algorithms for Symptom Management. In End of Life Care

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

End of life prescribing guidance

Care of the Dying Management in Severe Renal Failure

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Care of the Dying Management in Severe Renal Failure

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Supportive Care. End of Life Phase

Conservative Management of Uraemia

Using syringe pumps in palliative care

Palliative Care Impact Survey

Symptom Management Guidelines for End of Life Care

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Care of dying adults in the last days of life. Improving care at the very end of life.

Isle of Wight Syringe Driver Compatibility Guidelines

Lothian Palliative Care Guidelines POCKET EDITION 2004

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

BACKGROUND Measuring renal function :

End Stage Liver Disease Regional Audit Casenote Survey

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Palliative care for heart failure patients. Susan Addie

This survey aims to look at individual practice and can be completed by any healthcare professional.

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

What else is new (other symptoms) DR ANDREW DAVIES

Implementing the recommendation on medication management and symptom control

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

MND Just in Case kit Information for GPs

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Palliative Care. Pocketbook 4

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

The last days of life in hospital and at home

What s New 2003? What new treatments? What have you discontinued? More information please!

Alternative Routes of Drug Administration (analgesia) Dr Andrew Dickman Consultant Pharmacist

Palliative Care Formulary

PRIMARY CARE PALLIATIVE CARE FORMULARY

ADULT SYRINGE DRIVER PROTOCOL (T34)

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

POLICY / PROCEDURE FOR THE USE OF THE McKinley T34 SYRINGE DRIVER

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Guidelines for Syringe Driver Management in Palliative Care in New Zealand

Planning for the future; A guide to symptom control at end of life in advanced dementia

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

BREATHLESSNESS MANAGEMENT

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Palliative Prescribing - Pain

PRIMARY CARE PALLIATIVE CARE FORMULARY

BJF Acute Pain Team Formulary Group

McKinley T34 Syringe Pump Policy and Procedure

Palliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

Palliative Care. Guidelines for prescribing analgesic in palliative care THREE PRESCRIBING IN PALLIATIVE CARE GUIDELINES FOR MANAGING COMMON SYMPTOMS

Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

Syringe Pumps: Guidance for the use with babies, children and young people in the community setting within Worcestershire

SCHEDULE 2 THE SERVICES

Eastern Health and Social Services Board Palliative Care

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

Palliative care for patients with brain cancer

East Kent Prescribing Group

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

Regional Renal Training

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

Yorkshire Cancer Network

West Midlands Palliative Care Physicians. Palliative care. Guidelines for the use of drugs in symptom control

Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

AMBER Prescribing should only be undertaken in General Practice under the advice of the local hospice or specialist palliative care team.

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Syringe drivers. *precipitation may be seen at higher doses

Transcription:

Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24 hours. Indications: Patient unable to take medication orally due to: Persistent nausea and/ or vomiting. Dysphagia. Bowel obstruction or malabsorption. Reduced level of consciousness, such as in the last days of life. General information: Use your local protocol for setting up a syringe driver: see Lothian Policy. This guideline contains information about the stability and compatibilities of medication commonly given in a subcutaneous infusion in palliative care. Drugs, doses or combinations other than those listed in the charts should be used only on the recommendation of a palliative care specialist. Any recommendation given by the palliative care specialist should be clearly documented in the patient s notes. Practice Points: Prescribe the medication and the diluent for subcutaneous administration in a syringe driver over 24 hours. Subcutaneous medication in a syringe driver aims to maintain symptom control. If the patient has uncontrolled symptoms before the driver is started or during the 24 hour infusion, give a breakthrough dose of medication. Prescribe the correct breakthrough dose, as required, for each medication in the driver but avoid a volume over 1ml for subcutaneous bolus injection. Protect the syringe from direct light Check the syringe regularly as per local protocol for precipitation, cloudiness, particles, colour change. Prepare a new syringe every 24 hours. Contents: Detailed information about indications and doses are in other sections of the Palliative Care Guidelines Table 1: Single drug doses and indications Table 2: Morphine and one or two other drugs Table 3: and one or two other drugs Table 4: and one or two other drugs Table 5: and one or two other drugs

Table 1: Single drugs used in a subcutaneous infusion in Palliative Care Diluent: water for injections Single agent Indications and dose range Comments MORPHINE, in 1ml in 2ml DIAMORPHINE,,, 500mg powder ampoules OXYCODONE in 1ml in 2ml ALFENTANIL 1mg (1000micrograms) in 2ml, in 10ml Antiemetics CYCLIZINE in 1ml METOCLOPRAMIDE in 2ml HALOPERIDOL in 1ml in 2ml LEVOMEPROMAZINE 2 in 1ml Indications: nausea and vomiting (bowel obstruction or intracranial disease) Dose: 50- / 24 hours Indications: nausea and vomiting (gastric stasis/outlet obstruction, opioid) Dose: 20- / 24 hours Indications: opioid or metabolic induced nausea, delirium Dose: 2.5- / 24 hours Indications: Complex nausea, terminal delirium/ agitation Dose: 5-2 / 24 hours -antiemetic Dose: 25- / 24 hours - terminal sedation see Guideline Anticholinergics for chest secretions or bowel colic HYOSCINE BUTYLBROMIDE in 1ml GLYCOPYRRONIUM 200 micrograms in 1ml 600 micrograms in 3ml HYOSCINE HYDROBROMIDE 400 micrograms in 1ml 600 micrograms in 1ml Sedative MIDAZOLAM in 2ml (preferred) in 5ml Indications: chest secretions, bowel obstruction (colic, vomiting) Dose: 40- / 24 hours Indications: chest secretions or colic Dose: 600-1200 micrograms /24 hours Indications: chest secretions Dose: 400-1200 micrograms / 24 hours Indications: anxiety, muscle spasm/ myoclonus, seizures, terminal delirium/ agitation Dose: titrate according to symptoms and response Other medication occasionally given by SC route in palliative care 1st line opioid analgesic Can be diluted in a small volume Preferred for high opioid doses 2nd line opioid analgesic if morphine/ diamorphine not tolerated 3rd line opioid; seek specialist advice 1st line in stages 4 /5 chronic kidney disease Anticholinergic; reduces peristalsis Can cause redness, irritation at site Prokinetic Avoid if complete bowel obstruction or colic Long half life: can be given as a once daily SC injection Lowers blood pressure Usually combine with a benzodiazepine for terminal sedation. Long half life: can be given as a once or twice daily SC injection First line; non-sedative Second line; non-sedative Longer duration of action than hyoscine Second line; sedative Can precipitate delirium Anxiolytic (5-/ 24 hours) Muscle relaxant (5-/ 24 hours) Anticonvulsant (20-/ 24 hours) First line sedative (20- / 24 hours) DEXAMETHASONE Indications: bowel obstruction, raised Subcutaneous dose is the same as oral 4mg in 1ml intracranial pressure or intractable Available as different dose formulations so nausea and vomiting check preparation Dose: 2-16mg / 24 hours Do not mix with other drugs Can be given as a daily SC injection (in the morning) KETAMINE Indications: Complex pain Specialist supervision only see Guideline KETOROLAC in 1ml in 1ml OCTREOTIDE 200micrograms/ml (5ml multi-dose vial) Indication: bone/ inflammatory pain if patient in last days of life Dose: 10- / 24 hours Indications: intractable vomiting due to bowel obstruction, fistula discharge Dose: 300 900 micrograms / 24 hours Specialist supervision only Give an oral PPI if still able to swallow Long half life in frail patients: can be given as a twice daily SC injection High cost; some formulations v expensive Potent antisecretory agent Does not treat nausea Limit fluid intake to 1-1.5 litre/ 24 hrs

Table 2: Morphine These are not clinical doses to prescribe. Most patients will not need high doses. Read the relevant guideline(s) Glycopyrronium bromide 2 2 900micrograms 1200micrograms 3 400mg 2 3 4 900micrograms 1200micrograms 2 4 2 3 400mg 300micrograms 400micrograms Glycopyrronium 2 900micrograms 2 1200micrograms

Table 3: These are not clinical doses to prescribe. Most patients do not need high doses. Read the relevant guideline(s) Glycopyrronium bromide Ketorolac 2 3 3 42 1000micrograms 1200 micrograms 1400mg 1700mg 2 25 2 25 1200micrograms 1200micrograms 700mg 8 2 25 8 2 3 5 6 3 42 900 micrograms 900 micrograms 2 3 9 5 9 1 700mg 1 11 6 8 1600mg

Table 4: These are not clinical doses to prescribe. Most patients do not need high doses. Read the relevant guideline(s) () Ketorolac Do not mix - Do not mix - Incompatible Incompatible 1 1 1 1200micrograms 1200micrograms 8 3 3 300micrograms 400micrograms 800micrograms 1 1000micrograms 1

Table 5: These are not clinical doses to prescribe. Most patients do not need high doses. Read the relevant guideline(s) () Glycopyrronium bromide 4mg 4mg 5. 1100micrograms 1200micrograms 6mg 4. 5. 6mg 1200micrograms 1200micrograms 5. 6. 6 4 3. 6mg 700micrograms 800micrograms 3. 4. 3 4mg 2mg 5 2 2 3 3. 3 Resources 1. Palliative Care Formulary http://www.palliativedrugs.com Further reading: see website